VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. It is developing VYN202, an oral, small molecule BD2-selective BET inhibitor. VYN202 is an oral, small molecule BD2-selective BET inhibitor that has been designed to achieve potential class-leading potency and selectivity for BD2 vs. BD1. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	111M 94.78M 88.67M 81.07M 153M 10.59B 155M 1.05B 408M 5.32B 415M 406M 17.59B	P/E 2026 *	-22.2x	P/E 2027 *	-19.7x
Enterprise Value	111M 94.78M 88.67M 81.07M 153M 10.59B 155M 1.05B 408M 5.32B 415M 406M 17.59B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

08-13	Yarrow Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	RTW Biotech's Avere to go public in US in reverse merger with NextCure	AN
08-03	BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58	MT
07-29	RTW Biotech's Portfolio Company Completes Merger with Vyne Therapeutics	MT
07-27	Yarrow Bioscience, Inc.(NasdaqCM:YARW) added to NASDAQ Composite Index	CI
07-27	Yarrow Bioscience, Inc. completed the acquisition of VYNE Therapeutics Inc. from AI Biotechnology LLC, Nantahala Capital Management LLC, and other shareholders in a reverse merger transaction.	CI
07-27	Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101	MT
07-26	Yarrow Bioscience, Inc. announced that it has received $200 million in funding from a group of investors	CI
07-24	Top Premarket Decliners	MT
07-21	VYNE Approves 1-for-50 Reverse Stock Split	MT
07-10	VYNE Therapeutics Inc. Declares Special Cash Dividend, Payable on July 23, 2026	CI
07-10	VYNE Therapeutics Declares Estimated $0.38-Per-Share Special Cash Dividend Ahead of Yarrow Merger	MT
06-15	Yarrow Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

08-03	BTIG Upgrades Yarrow Bioscience to Buy From Neutral, Price Target is $58	MT
25-07-31	BTIG Research Downgrades VYNE Therapeutics to Neutral From Buy	MT
24-11-18	BTIG Initiates VYNE Therapeutics at Buy With $8 Price Target	MT
23-05-12	Cantor Fitzgerald Adjusts Price Target on VYNE Therapeutics to $9 From $5, Maintains Overweight Rating	MT
23-03-14	HC Wainwright Adjusts Price Target on VYNE Therapeutics to $28 From $1.50, Maintains Buy Rating	MT

08-13	Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update	BU
07-23	VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience	AQ
07-21	VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience	AQ
07-10	VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience	AQ
05-21	VYNE Therapeutics : Yarrow Bioscience Investor Presentation	PU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
FOAMIX PHARMACEUTICALS LTD.	-.--%	-16.94%	-	-	19.05M
WUXI APPTEC CO., LTD.	-4.31%	-6.62%	+65.79%	+98.02%	72.12B
ARGENX SE	-4.19%	+1.05%	+52.79%	+85.53%	65.85B
BIONTECH SE	-3.22%	+23.17%	+1.75%	-5.23%	29.28B
INSMED INCORPORATED	-1.42%	-3.38%	-5.99%	+465.34%	27.47B
WUXI BIOLOGICS (CAYMAN) INC.	-4.71%	+5.29%	+47.63%	+8.97%	26.7B
GENMAB A/S	-1.81%	+0.38%	+34.52%	-18.33%	20.06B
PHARMAESSENTIA CORPORATION	+5.36%	+4.61%	+270.18%	+415.10%	18.22B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-2.79%	+0.10%	+12.09%	+549.69%	16.4B
EXELIXIS, INC.	+0.87%	+4.26%	+41.21%	+150.80%	13.4B
Average	-1.62%	+5.35%	+57.77%	+194.43%	32.17B
Weighted average by Cap.	-2.83%	+3.13%	+54.39%	+151.30%

Foamix Pharmaceuticals Ltd. Stock Nasdaq

Stocks

IL0011334385

Biotechnology & Medical Research

Valuation: Foamix Pharmaceuticals Ltd.

Latest news : Foamix Pharmaceuticals Ltd.

Last Transcript: Foamix Pharmaceuticals Ltd.

Analysts' recommendations: Foamix Pharmaceuticals Ltd.

Press Releases: Foamix Pharmaceuticals Ltd.

Bio Therapeutic Drugs

Financials

Company Profile

	2026 *	2027 *
Net sales	-	-
Net income	-38.54M -33.03M -30.9M -28.25M -53.32M -3.69B -53.88M -366M -142M -1.85B -145M -142M -6.13B	-66.89M -57.33M -53.63M -49.03M -92.53M -6.41B -93.51M -635M -247M -3.22B -251M -246M -10.64B
Net Debt	-	-